title: A comparison of four buprenorphine dosing regimens using open-dosing procedures: is twice-weekly dosing possible?
abstract: OBJECTIVE
  To compare opioid withdrawal symptoms during 24-, 48-, 72- and 96-hour buprenorphine dosing regimens and to evaluate subjects' preferences for these different dosing schedules.
  
  
  METHODS
  Fourteen opioid-dependent subjects participated in this study. They received daily sublingual maintenance doses of 4 mg/70 kg (n = 4) or 8 mg/70 kg (n = 10) of buprenorphine.
  
  
  METHODS
  In the first study subjects received, in a random order, four dosing regimens for five repetitions of each: daily maintenance doses every 24 hours (4 or 8 mg/70 kg), double the daily maintenance dose every 48 hours (8 or 16 mg/70 kg), triple the daily maintenance dose every 72 hours (12 or 24 mg/70 kg), and quadruple the daily maintenance dose every 96 hours (16 or 32 mg/70 kg). Measures of subjective and observer opioid withdrawal symptoms were assessed prior to receipt of each dose. In a second study, subjects chose between the different dosing regimens.
  
  
  RESULTS
  Some withdrawal ratings increased during the less frequent dosing schedules in the first study. In the second study, 46% of subjects preferred the quadruple-every-fourth-day dosing regimen over every other option, and only 14% preferred to be dosed daily.
  
  
  CONCLUSIONS
  These results suggest that some opioid-dependent outpatients are willing and able to endure the withdrawal symptoms associated with less than daily dosing, and a twice-weekly dosing regimen may be possible.
authors.affiliation: Department of Psychiatry, University of Vermont, Burlington, USA. petry@psychiatry.uchc.edu
authors.forename: N M
authors.initials: NM
authors.lastname: Petry
authors.forename: W K
authors.initials: WK
authors.lastname: Bickel
authors.forename: G J
authors.initials: GJ
authors.lastname: Badger
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D002047:Buprenorphine / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009294:Narcotics / Q000008:administration & dosage* / Q000009:adverse effects; D009293:Opioid-Related Disorders / Q000534:rehabilitation*; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D009294:Narcotics; D002047:Buprenorphine